Skin Cancer | Tumor

Rage at the Sun

May 7th 2021, 4:00pm


A melanoma survivor pens a poem about his cancer journey, losing his wife to melanoma and how he lives his life after these experiences.

Prolonging Recurrence-Free Survival With Keytruda Does Not Come at the Price of Reduced Quality of Life for Patients with Melanoma

May 7th 2021, 1:00pm


Patients with melanoma treated with Keytruda had improved recurrence-free survival without an effect on their quality of life.

If You Can Spot It, You Can Stop It: Schedule an Annual Skin Exam With Your Dermatologist

May 3rd 2021, 12:45pm


When caught and treated early, skin cancer is highly curable. When allowed to progress, however, it can cause disfigurement and even death.

Stories of Loss and Survival with Melanoma

April 30th 2021, 4:00pm


Which story – of hope or fear – is the best experience to relate to help another?

Effects of Keytruda Sustained After 3.5 Years in High-Risk Melanoma

April 23rd 2021, 1:00pm


In patients with resected high-risk stage 3 cutaneous melanoma, distant metastasis-free survival at 3.5 years was 65.3% in patients treated with Keytruda compared with 49.4% in those treated with placebo, which was also consistent in patients with PD-L1-positive tumors.

Keytruda Shows Promise for Certain Patients with Cutaneous Squamous Cell Carcinoma

April 22nd 2021, 1:00pm


Keytruda demonstrated clinical benefit for patients with recurrent and metastatic disease, according to an expert.

Delayed Surgery Possible With Surveillance in Patients With Sentinel Lymph Node Positive Melanoma

April 20th 2021, 1:00pm


Active surveillance in sentinel lymph node positive melanoma could delay surgery but may result in the same risk of the cancer coming back.

Chronic Side Effects from Anti-PD-1 Therapy Use in Patients with Advanced Skin Cancer More Common Than Previously Believed

April 12th 2021, 1:00pm


Chronic immune-related adverse events from anti-PD-1 therapy occur in many patients with advanced melanoma, but shouldn’t deter them from seeking treatment that can provide long-term survival, according to an expert from Vanderbilt University Medical Center.

FDA's Libtayo Approval Offers Another Option for Skin Cancer Subtype With Previous 'Historically Limited' Treatments

April 8th 2021, 6:00pm


An expert spoke with CURE® about the FDA’s recent approval of Libtayo to treat patients with locally advanced basal cell carcinoma who previously had only one therapy option for locally advanced disease.

Immunotherapy, Other Therapies May Have Improved Overall Survival in Melanoma Brain Metastasis

March 19th 2021, 6:00pm


FDA approval of immunotherapies and BRAF/MEK inhibitors may have impacted overall survival, with a change from seven months between 2010 and 2014 to 13 months between 2015 and 2019.